Skip to main content
Top
Published in: Endocrine 3/2021

01-12-2021 | McCune-Albright syndrome | Original Article

Mild progressive osseous heteroplasia overlap syndrome with PTH and TSH resistance appearing during adolescence and not early childhood

Authors: Kayo Ozaki, Akari Mituboshi, Masashi Nagai, Atushi Nishiyama, Gen Nishimura, Naoya Morisada, Kazumoto Iijima

Published in: Endocrine | Issue 3/2021

Login to get access

Abstract

Purpose

Progressive osseous heteroplasia (POH), a genetic disorder, is associated with Albright’s hereditary osteodystrophy (AHO), pseudohypoparathyroidism, and primary osteoma cutis and has common features of superficial ossification and GNAS-inactivating mutations. Disorders due to GNAS-inactivating mutations are classified as “inactivating parathyroid hormone (PTH)/PTHrP signaling disorder type 2.” This study reports a case of mild POH overlap syndrome to improve understanding of genotype–phenotype correlations.

Methods

A 13-year and 6-month-old Japanese boy was referred to our hospital with a chief complaint of the lower limb length difference. He underwent clinical, biochemical, radiological, and genetic studies.

Results

He showed sporadic GNAS mutation, deep ectopic ossification, small for gestational age (SGA), congenital tooth defect, and lack of AHO features; he met the diagnostic criteria for POH, and mild PTH and TSH resistance was detected. He had constant hyperphosphatasemia and hypocalciuria. At the age of 10 years, he occasionally experienced high iPTH levels. The pituitary stimulation test showed a normal response of all hormones at 3 years of age, but TSH response was decreased (previously 0.770, peak value 4.144 μIU/mL) in the TRH loading test at age 13 years and 6 months. DNA analysis showed a heterozygous p.D189MfsTer14 mutation of GNAS. The parents did not carry this mutation.

Conclusion

We report a rare case of POH overlap syndrome with PTH/TSH resistance that appeared in adolescence rather than early childhood. Cases diagnosed with POH in early childhood also require reassessment during adolescence. Further studies of the GNAS heterozygous mutation p.D189MfsTer14 may reveal factors involved in POH overlap syndrome.
Literature
1.
go back to reference G. Mantovani, M. Bastepe, D. Monk, L. De Sanctis, S. Thiele, A. Usardi, S.F. Ahmed, R. Bufo, T. Choplin, G. De Filippo, G. Devernois, Diagnosis and management of pseudohypoparathyroidism and related disorders: First international Consensus Statement. Nat. Rev. Endocrinol. 14, 476–500 (2018)CrossRef G. Mantovani, M. Bastepe, D. Monk, L. De Sanctis, S. Thiele, A. Usardi, S.F. Ahmed, R. Bufo, T. Choplin, G. De Filippo, G. Devernois, Diagnosis and management of pseudohypoparathyroidism and related disorders: First international Consensus Statement. Nat. Rev. Endocrinol. 14, 476–500 (2018)CrossRef
2.
go back to reference N.S. Adegbite, M. Xu, F.S. Kaplan, E.M. Shore, R.J. Pignolo, Diagnostic and mutational spectrum of progressive osseous heteroplasia (POH) and other forms of GNAS-based heterotopic ossification. Am. J. Med. Genet. A 146A, 1788–1796 (2008)CrossRef N.S. Adegbite, M. Xu, F.S. Kaplan, E.M. Shore, R.J. Pignolo, Diagnostic and mutational spectrum of progressive osseous heteroplasia (POH) and other forms of GNAS-based heterotopic ossification. Am. J. Med. Genet. A 146A, 1788–1796 (2008)CrossRef
4.
go back to reference S. Thiele, G. Mantovani, A. Barlier, V. Boldrin, P. Bordogna, L. De Sanctis, F.M. Elli, K. Freson, I. Garin, V. Grybek, P. Hanna, From pseudohypoparathyroidism to inactivating PTH/PTHrP signalling disorder (iPPSD), a novel classification proposed by the EuroPHP network. Eur. J. Endocrinol. 175, P1–P17 (2016)CrossRef S. Thiele, G. Mantovani, A. Barlier, V. Boldrin, P. Bordogna, L. De Sanctis, F.M. Elli, K. Freson, I. Garin, V. Grybek, P. Hanna, From pseudohypoparathyroidism to inactivating PTH/PTHrP signalling disorder (iPPSD), a novel classification proposed by the EuroPHP network. Eur. J. Endocrinol. 175, P1–P17 (2016)CrossRef
5.
go back to reference G. Mantovani, A. Spada, F.M. Elli, Pseudohypoparathyroidism and Gsα-cAMP-linked disorders: current view and open issues. Nat. Rev. Endocrinol. 12, 347–356 (2016)CrossRef G. Mantovani, A. Spada, F.M. Elli, Pseudohypoparathyroidism and Gsα-cAMP-linked disorders: current view and open issues. Nat. Rev. Endocrinol. 12, 347–356 (2016)CrossRef
6.
go back to reference E.M. Shore, J. Ahn, S.J. De Beur, M. Li, M. Xu, R.M. Gardner, M.A. Zasloff, M.P. Whyte, M.A. Levine, F.S. Kaplan, Paternally inherited inactivating mutations of the GNAS1 gene in progressive osseous heteroplasia. N. Engl. J. Med. 346, 99–106 (2002)CrossRef E.M. Shore, J. Ahn, S.J. De Beur, M. Li, M. Xu, R.M. Gardner, M.A. Zasloff, M.P. Whyte, M.A. Levine, F.S. Kaplan, Paternally inherited inactivating mutations of the GNAS1 gene in progressive osseous heteroplasia. N. Engl. J. Med. 346, 99–106 (2002)CrossRef
7.
go back to reference A. Pereda, F.M. Elli, S. Thiele, L. de Sanctis, A. Rothenbuhler, P. Hanna, B. Francou, D.A. Ertl, G.P. de Nanclares, A. Linglart, G. Mantovani, Inactivating PTH/PTHrP signaling disorders (iPPSDs): evaluation of the new classification in a multicenter large series of 544 molecularly characterized patients. Eur. J. Endocrinol. 184, 311–320 (2021)CrossRef A. Pereda, F.M. Elli, S. Thiele, L. de Sanctis, A. Rothenbuhler, P. Hanna, B. Francou, D.A. Ertl, G.P. de Nanclares, A. Linglart, G. Mantovani, Inactivating PTH/PTHrP signaling disorders (iPPSDs): evaluation of the new classification in a multicenter large series of 544 molecularly characterized patients. Eur. J. Endocrinol. 184, 311–320 (2021)CrossRef
8.
go back to reference R.J. Pignolo, G. Ramaswamy, J.T. Fong, E.M. Shore, F.S. Kaplan, Progressive osseous heteroplasia: diagnosis, treatment, and prognosis. Appl. Clin. Genet. 8, 37–48 (2015)CrossRef R.J. Pignolo, G. Ramaswamy, J.T. Fong, E.M. Shore, F.S. Kaplan, Progressive osseous heteroplasia: diagnosis, treatment, and prognosis. Appl. Clin. Genet. 8, 37–48 (2015)CrossRef
9.
go back to reference M. Bastepe, GNAS mutations and heterotopic ossification. Bone 109, 80–85 (2018)CrossRef M. Bastepe, GNAS mutations and heterotopic ossification. Bone 109, 80–85 (2018)CrossRef
10.
go back to reference M. Lebrun, N. Richard, G. Abeguilé, A. David, A.C. Dieux, H. Journel, D. Lacombe, G. Pinto, S. Odent, J.P. Salles, A. Taieb, Progressive osseous heteroplasia: a model for the imprinting effects of GNAS inactivating mutations in humans. J. Clin. Endocrinol. Metab. 95, 3028–3038 (2010)CrossRef M. Lebrun, N. Richard, G. Abeguilé, A. David, A.C. Dieux, H. Journel, D. Lacombe, G. Pinto, S. Odent, J.P. Salles, A. Taieb, Progressive osseous heteroplasia: a model for the imprinting effects of GNAS inactivating mutations in humans. J. Clin. Endocrinol. Metab. 95, 3028–3038 (2010)CrossRef
11.
go back to reference F.M. Elli, A.M. Barbieri, P. Bordogna, P. Ferrari, R. Bufo, E. Ferrante, E. Giardino, P. Beck-Peccoz, A. Spada, G. Mantovani, Screening for GNAS genetic and epigenetic alterations in progressive osseous heteroplasia: first Italian series. Bone 56, 276–280 (2013)CrossRef F.M. Elli, A.M. Barbieri, P. Bordogna, P. Ferrari, R. Bufo, E. Ferrante, E. Giardino, P. Beck-Peccoz, A. Spada, G. Mantovani, Screening for GNAS genetic and epigenetic alterations in progressive osseous heteroplasia: first Italian series. Bone 56, 276–280 (2013)CrossRef
12.
go back to reference I.M. Gelfand, R.S. Hub, E.M. Shore, F.S. Kaplan, L.A. DiMeglio, Progressive osseous heteroplasia-like heterotopic ossification in a male infant with pseudohypoparathyroidism type Ia: a case report. Bone 40, 1425–1428 (2007)CrossRef I.M. Gelfand, R.S. Hub, E.M. Shore, F.S. Kaplan, L.A. DiMeglio, Progressive osseous heteroplasia-like heterotopic ossification in a male infant with pseudohypoparathyroidism type Ia: a case report. Bone 40, 1425–1428 (2007)CrossRef
Metadata
Title
Mild progressive osseous heteroplasia overlap syndrome with PTH and TSH resistance appearing during adolescence and not early childhood
Authors
Kayo Ozaki
Akari Mituboshi
Masashi Nagai
Atushi Nishiyama
Gen Nishimura
Naoya Morisada
Kazumoto Iijima
Publication date
01-12-2021
Publisher
Springer US
Published in
Endocrine / Issue 3/2021
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-021-02821-y

Other articles of this Issue 3/2021

Endocrine 3/2021 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.